516 rue Pierre et Marie Curie
Vaiomer is a French biotech company and contract research organization (CRO) expert in tissue and blood microbiota. The company was created in 2011 on the pioneering work of INSERM that unraveled the causal role exerted by tissue and blood microbiome in the initiation of an inflammatory cascade leading to cardiometabolic disorders. The vocation of Vaiomer is to contribute to the discovery of innovative tools, biomarkers and therapeutic targets related to tissue microbiome. This new concept helps to establish early prognosis and therapies of numerous diseases such as cardiometabolic diseases (obesity, diabetes, NASH, NAFLD, liver fibrosis, cirrhosis, cardiac failure, etc.), neurodegenerative disorders (Alzheimer, Parkinson, etc.) or infectious diseases (AIDS, septicemia, etc.). To achieve this goal, Vaiomer has set up state-of-the-art technology in molecular biology, 16S metagenomics, transcriptomics and computational biology to identify bacterial community profiles in blood and tissues. Our assays (both quantitative and qualitative) are exhaustive (non a priori approach) and particularly sensitive. The Vaiomer personnel have been trained in world-class institutions and have proven expertise in the following areas:
- Biomarker and therapeutic target discovery
- Development and implementation of real-time qPCR assays for bacterial biomarkers
- DNA and RNA sample preparation for NGS HT DNA sequencing and transcriptomic analysis
- Bioinformatic and biostatistical analysis of metagenomic and transcriptomic data
- General molecular biology and cell biology skills
Within MICROB-PREDICT, thanks to our unique expertise, our company will perform 16S metagenomics analysis of buffy coat and mucosal samples.